Leukemia inhibitory factor enhances regeneration in skeletal muscles after myoblast transplantation.
Cell-based therapies, such as myoblast transfer therapy, are likely to become an integral part of any approach to treat myopathies such as Duchenne muscular dystrophy. Previous studies have shown that an increased level of regeneration in the host muscle enhances incorporation of donor myoblasts. Leukemia inhibitory factor (LIF) increases the number of dystrophic fibers expressing dystrophin after myoblast transplantation and enhances regeneration in injured and diseased muscle. Morphometric analysis was used to investigate whether an increased level of regeneration is induced by LIF after myoblast transplantation. We found that, in muscles treated with LIF, the number of fibers undergoing regeneration was increased. The increased incorporation of donor myoblasts and thus dystrophin expression induced by LIF may be due, at least in part, to an increased level of regeneration of dystrophic muscle.
White
J D
JD
Melbourne Neuromuscular Research Center, St. Vincent's Hospital, Victoria Parade, Fitzroy, Victoria, Australia. jwhite@anhb.uwa.edu.au
Bower
J J
JJ
Kurek
J B
JB
Austin
L
L
D000818:Animals; D017690:Cell Transplantation; D016189:Dystrophin / Q000096:biosynthesis; D006131:Growth Inhibitors / Q000494:pharmacology*; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018485:Muscle Fibers, Skeletal / Q000637:transplantation; D018482:Muscle, Skeletal / Q000166:cytology / Q000502:physiology*; D012038:Regeneration / Q000187:drug effects*; D014183:Transplantation, Heterologous
D016189:Dystrophin; D006131:Growth Inhibitors; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; C507838:Lif protein, mouse; D008222:Lymphokines